Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Janux Therapeutics, Inc.NASDAQ: JANX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 29.7% from a year ago
Cash & equivalents stood at $51.83M at the end of Q1 FY2026, down 29.7% from a year earlier and down 1.0% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.
Context
- Cash & equivalents amounted to 5.0% of total assets at the end of Q1 FY2026, down 2.0 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -29.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 52.33M USD
- Year-over-year change
- -87.8%
- 4-year CAGR
- +10.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.33M | -87.8% |
| FY2024 | 2024-12-31 | 430.61M | +2142.2% |
| FY2023 | 2023-12-31 | 19.21M | -62.7% |
| FY2022 | 2022-12-31 | 51.43M | +44.5% |
| FY2021 | 2021-12-31 | 35.58M | — |
Cash & Equivalents vs competitors
How JANX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -29.7% is the 7th highest of 10, against a peer median of -21.9%.
- Cash & equivalents amounts to 5.0% of total assets for JANX, versus a peer median of 27.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $460.7M USD | +65.2% | +4.7% | 27.4% | |
| Mar 2026 | €301.65M EUR | +24.2% | +32.5% | 55.5% | |
| Sep 2026 | $212.84M USD | -21.9% | +218.0% | 42.1% | |
| Mar 2026 | $75.08M USD | -2.1% | -17.3% | 18.6% | |
| Mar 2026 | $73.68M USD | -30.6% | +7.1% | 30.4% | |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $55.17M USD | +34.4% | -4.3% | 26.9% | |
| Mar 2026 | $51.83M USD | -29.7% | +0.6% | 5.0% | |
| Mar 2026 | $28.83M USD | -39.4% | -59.7% | 8.0% | |
| Sep 2026 | $26.95M USD | -25.2% | -0.6% | 3.7% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding JANX) | — | -21.9% | -0.6% | 27.4% | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.58M | 51.43M | 19.21M | 430.61M | 52.33M |
| Short-term Investments | 339.38M | 275.59M | 324.82M | 594.57M | 914.23M |
| Net Receivables | 0 | 700K | 2.16M | 5.38M | 6.43M |
| Inventory | 0 | (700K) | 0 | 0 | 0 |
| Other Current Assets | 0 | 5.42M | 0 | 0 | 0 |
| Total Current Assets | 377.02M | 332.44M | 349.24M | 1.03B | 975.89M |
| Property, Plant & Equipment (Net) | 1.6M | 29.37M | 27.84M | 24.15M | 22.25M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 816K | 0 | 0 | 816K |
| Tax Assets | 0 | 0 | 0 | 0 | 5.96M |
| Other Non-current Assets | 1.21M | 1.39M | 3.33M | 3.7M | 2.61M |
| Total Non-current Assets | 2.81M | 31.57M | 31.17M | 27.85M | 31.64M |
| Total Assets | 379.82M | 364.01M | 380.41M | 1.06B | 1.01B |
| Account Payables | 2.46M | 2.16M | 2.42M | 4.03M | 4.97M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.39M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 5.16M | 5.41M | 1.71M | 0 | 0 |
| Other Current Liabilities | 2.37M | 5.51M | 3.3M | 4.57M | 13.04M |
| Total Current Liabilities | 12.8M | 16.51M | 13.03M | 17.46M | 25M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 5.96M |
| Deferred Revenue (Non-current) | 700K | 2.22M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 700K | 26.76M | 23.03M | 21.28M | 25.7M |
| Total Liabilities | 13.5M | 43.27M | 36.06M | 38.74M | 50.7M |
| Common Stock | 41K | 42K | 46K | 59K | 60K |
| Retained Earnings | (47.41M) | (110.47M) | (168.76M) | (237.76M) | (351.38M) |
| Accumulated OCI | (270K) | (1.54M) | 665K | 2.16M | 4.32M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 366.33M | 320.74M | 344.35M | 1.02B | 956.82M |
| Total Debt | 194K | 25.31M | 24.54M | 23.03M | 22.14M |
| Net Debt | (35.39M) | (26.12M) | 5.34M | (407.58M) | (30.2M) |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.